Schrodinger saw the highest growth of 2.99% in patent filings in May and 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Schrodinger‘s patent filings and grants. Buy the databook here.
Schrodinger has been focused on protecting inventions in United States(US) with eight publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 55% filings and 100% grants. The United States(US), World Intellectual Property Organization(WIPO), Argentina(AR), and Denmark(DK) patent Office are among the top ten patent offices where Schrodinger is filings its patents. Among the top granted patent authorities, Schrodinger has 100% of its grants in United States(US).
Roche could be the strongest competitor for Schrodinger
Patents related to rare diseases and precision and personalized medicine lead Schrodinger's portfolio
Schrodinger has the highest number of patents in rare diseases followed by, precision and personalized medicine and immuno-oncology. For rare diseases, nearly 38% of patents were filed and 50% of patents were granted in Q2 2024.
Breast cancer related patents lead Schrodinger portfolio followed by colon cancer, and liver cancer
Schrodinger has highest number of patents in breast cancer followed by colon cancer, liver cancer, lung cancer, and ovarian cancer.
For comprehensive analysis of Schrodinger's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.